EMD Electronics Expands Semiconductor Manufacturing Capacities for the World's Largest Integrated Specialty Gases Facility in Hometown, Pennsylvania

Agreement with the Commonwealth of Pennsylvania supports the expansion of manufacturing capacities for the semiconductor industry. The roughly $300 million investment is part of the company's 'Level Up' program aimed at accelerating its innovation and capacities.

EMD Electronics, the Electronics business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced an agreement with the Commonwealth of Pennsylvania to support expansion plans at its semiconductor manufacturing site in Hometown. This expansion is part of the company's Level Up growth program, announced by its Electronics business sector in late 2021, which aims to invest over $3.5 billion in innovation and capacity expansion projects by 2025. The roughly $300 million investment in the Hometown site will create the world's largest integrated Specialty Gases facility and support the success of Merck's Semiconductor Solutions business, one of its "Big 3" growth engines

New Plant Rendering
New Plant Rendering
Rendering of the new plant at EMD Electronics' Tamaqua, PA site.

"Despite near-term cautions due to the industry's cyclical nature, the demand for semiconductor materials remains very promising long term," said Kai Beckmann, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Electronics. "Having domestic production capacity for critical electronics components has become a high priority for many economies. As the brains of modern electronics, semiconductors enable technology critical to economic growth and global competitiveness. We're poised to support our customers as the most local of global partners in the inextricable rise of semiconductor innovation."

"Together with EMD Electronics, we are planting a flag here in Pennsylvania and showing the rest of the country that we are going to be a leader in the semiconductor industry, helping our country produce vital high-tech products that power everything from our smartphones to our cars," said Pennsylvania governor Josh Shapiro. "I'm proud the Commonwealth of Pennsylvania is partnering with EMD Electronics on the largest integrated specialty gases facility in the world. This investment will create high-paying jobs in Schuylkill County and should serve as a shining example of how the Commonwealth and leading businesses can work together to foster innovation and advance economic development here in Pennsylvania."

The agreement includes incentive targets associated with at least 68 new jobs and roughly $300 million in potential investments that will enable Merck KGaA, Darmstadt, Germany to capture and grow its semiconductor materials business in North America and Europe and provide supplemental capacity to supply Asia.

The company expects to hire at least 68 employees at full ramp-up, including technicians and engineers. Those interested in exploring career opportunities at the site should visit the EMD Electronics career website.

"We have been the employer of choice in Hometown for almost 50 years. Our commitment to level up our business in Schuylkill County bodes well for the community and its global impact on the semiconductor industry. We appreciate the efforts on the part of the Commonwealth of Pennsylvania to recognize the value of our growth plans and work with us to make this expansion possible. We would also like to acknowledge the support of Pennsylvania Governor Josh Shapiro, State Senator Dave Argall, Secretary of Community and Economic Development Rick Siger, and other local elected officials for their support," said Jeff White, President, EMD Electronics.

"EMD Electronics has been an anchor manufacturing facility in Schuylkill County for decades during which time it has grown to be one of the most sophisticated industrial complexes in all of Pennsylvania," noted Frank Zukas, President of the Schuylkill Economic Development Corporation. "These planned expansion projects will allow our community to play a major part in the development of the semiconductor ecosystem in the U.S."

Level Up program continues to deliver critical capacity to fuel accelerated semiconductor growth in the U.S.

Driven by the accelerated industry growth, the Electronics Business of Merck KGaA, Darmstadt, Germany is delivering a remarkable track record of investment execution since the introduction of its Level Up growth program and the announcement of significantly more than $3.5 billion in innovation and capacities in the U.S., Germany, and Asia by the end of 2025.

As part of this investment plan, approximately $1 billion will be allocated to supporting R&D and manufacturing capacities in the company's Electronics business sector in the U.S., primarily in its Arizona, California, Texas, and Pennsylvania sites. For instance, by the end of the first half of 2023, the company expects to start operations at its new factory in the greater Phoenix, Arizona area for the manufacture of equipment for its Delivery Systems & Services (DS&S) business. The new site will enable the company to further grow its gas and chemical delivery systems business and provide key supplemental capacity to the semiconductor ecosystem.

Related Images

New Plant Rendering
New Plant Rendering
Rendering of the new plant at EMD Electronics' Tamaqua, PA site.
EMD Electronics' Tamaqua, PA site
EMD Electronics' Tamaqua, PA site
Aerial photograph of EMD Electronics' Tamaqua, PA site.

About EMD Electronics

EMD Electronics is the North American electronics business of Merck KGaA, Darmstadt, Germany. EMD Electronics' portfolio covers a broad range of products and solutions, including high-tech materials and solutions for the semiconductor industry as well as liquid crystals and OLED materials for displays and effect pigments for coatings and cosmetics. Today, EMD Electronics has approximately 2,000 employees around the country, with regional offices in Tempe (AZ) and Philadelphia (PA). For more information, please visit www.emd-electronics.com.

Contact Information:

Johanna Batista
Communications Business Partner
johanna.batista@emdgroup.com
+1 (848) 230 5400

SOURCE: EMD Electronics

.

View source version on accesswire.com:
https://www.accesswire.com/748677/EMD-Electronics-Expands-Semiconductor-Manufacturing-Capacities-for-the-Worlds-Largest-Integrated-Specialty-Gases-Facility-in-Hometown-Pennsylvania

News Provided by ACCESSWIRE via QuoteMedia

MRK
The Conversation (0)
Merck Announces First-Quarter 2023 Financial Results

Merck Announces First-Quarter 2023 Financial Results

  • First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines
  • Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of Foreign Exchange, Growth Was 15%
    • KEYTRUDA Sales Grew 20% to $5.8 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 24%
    • GARDASIL/GARDASIL 9 Sales Grew 35% to $2.0 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 43%
    • LAGEVRIO Sales Declined 88% to $392 Million; Excluding the Impact of Foreign Exchange, Sales Declined 87%
  • GAAP EPS Was $1.11; Non-GAAP EPS Was $1.40; GAAP and Non-GAAP EPS Include $0.52 of Charges Related to Acquisition of Imago and Collaboration and Licensing Agreement With Kelun-Biotech
  • Announced Proposed Acquisition of Prometheus Biosciences to Strengthen Immunology Pipeline
  • Presented Compelling Data From Innovative Cardiovascular Pipeline With:
    • Positive Phase 3 Results for Sotatercept
    • Positive Phase 2b Results for MK-0616; Plans to Start Phase 3 Studies in 2023
  • Advanced Oncology Research Efforts, Sharing Notable Progress for Earlier Stages of Disease in Certain Tumor Types, Including:
    • Positive Topline Results From Phase 3 KEYNOTE-671 Trial
    • Positive Detailed Results in Collaboration With Moderna From Phase 2b KEYNOTE-942/mRNA-4157-P201 Trial
  • 2023 Financial Outlook
    • Raises and Narrows Expected Full-Year 2023 Worldwide Sales Range To Be Between $57.7 Billion and $58.9 Billion, Including Negative Impact of Foreign Exchange of Approximately 2 Percentage Points; Outlook Includes Approximately $1.0 Billion of LAGEVRIO Sales
    • Lowers and Narrows Expected Full-Year 2023 GAAP EPS Range To Be Between $5.85 and $5.97, Reflecting Zetia Antitrust Litigation Settlement
    • Raises and Narrows Expected Full-Year 2023 Non-GAAP EPS Range To Be Between $6.88 and $7.00, Including Negative Impact of Foreign Exchange of Approximately 4 Percentage Points
    • Outlook Does Not Reflect Any Impact From Proposed Acquisition of Prometheus Biosciences, Which Is Expected to Close in Third Quarter 2023, and Would Result in a One-Time Charge to Both GAAP and Non-GAAP Results of Approximately $10.3 Billion or Approximately $4.00 per Share

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2023.

�Inspired by our commitment to bring bold science forward to address critical unmet patient needs, we began 2023 with significant advancements across our innovative pipeline," said Robert M. Davis, chairman and chief executive officer, Merck. "Our first-quarter results are a reflection of the focused execution of our science-led strategy, strong performance across our key growth drivers, continued momentum commercially and operationally, and most importantly the collective and dedicated efforts of our colleagues around the world. I'm proud of the progress we've made, and we will continue to move with speed and agility to deliver value for patients and shareholders, now and well into the future."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.

Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI)

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
OTC:BCTXF

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health

Highlights:

  • Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University.
  • Merck to provide KEYTRUDA® for use in the combination study.
  • The Investigator Grant validates and will build on the encouraging preliminary data from BriaCell’s combination study of Bria-IMT™ with KEYTRUDA® (Link).

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT, OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that Dr. Saveri Bhattacharya, a board-certified medical oncologist and recognized expert in breast cancer treatment at the Sidney Kimmel Cancer Center – Jefferson Health in Philadelphia, PA, has been selected to receive support from the Merck Investigator Studies Program (“MISP”). The Investigator Grant is a highly coveted award granted by Merck & Co., Inc. (“Merck”) (NYSE: MRK) to leading investigators with highly innovative clinical studies.

Keep reading...Show less

Merck Announces Q4 and Full-Year 2019 Financial Results

Merck (NYSE:MRK) reported quarterly worldwide sales at US$11.9 billion in Q4 in its financial results for the fourth quarter of 2019 and its full fiscal 2019 year.

As quoted in the press release:

Keep reading...Show less
OTC:BCTXF

BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer:

  • Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.);
  • Bria-IMT™ in combination with INCMGA00012 (by Incyte Corporation).

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT, OTCQB:BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that the data of its clinical studies with its lead product candidate, Bria-IMT™, will be presented the at the Annual Symposium of Society of Surgical Oncology (SSO) 2020 – International Conference on Surgical Cancer Care taking place March 25-28 in Boston, MA.

Keep reading...Show less
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×